Sunday 27 November 2011

Tramadol axcount




Tramadol axcount may be available in the countries listed below.


Ingredient matches for Tramadol axcount



Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Tramadol axcount in the following countries:


  • Germany

International Drug Name Search

Monday 21 November 2011

Actos


Actos is a brand name of pioglitazone, approved by the FDA in the following formulation(s):


ACTOS (pioglitazone hydrochloride - tablet; oral)



  • Manufacturer: TAKEDA PHARMS NA

    Approval date: July 15, 1999

    Strength(s): EQ 15MG BASE, EQ 30MG BASE, EQ 45MG BASE [RLD]

Has a generic version of Actos been approved?


No. There is currently no therapeutically equivalent version of Actos available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Actos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pharmaceutical composition
    Patent 5,965,584
    Issued: October 12, 1999
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES




  • Pharmaceutical composition
    Patent 6,150,383
    Issued: November 21, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,150,384
    Issued: November 21, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE




  • Pharmaceutical composition
    Patent 6,166,042
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE




  • Pharmaceutical composition
    Patent 6,166,043
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS




  • Pharmaceutical composition
    Patent 6,172,090
    Issued: January 9, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS




  • Pharmaceutical composition
    Patent 6,211,205
    Issued: April 3, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,271,243
    Issued: August 7, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION




  • Pharmaceutical composition
    Patent 6,303,640
    Issued: October 16, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • August 9, 2016
      ✓ 
      Patent use: METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,329,404
    Issued: December 11, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES



See also...

  • Actos Consumer Information (Drugs.com)
  • Actos Consumer Information (Wolters Kluwer)
  • Actos Consumer Information (Cerner Multum)
  • Actos Advanced Consumer Information (Micromedex)
  • Actos AHFS DI Monographs (ASHP)
  • Pioglitazone Consumer Information (Wolters Kluwer)
  • Pioglitazone Consumer Information (Cerner Multum)
  • Pioglitazone Advanced Consumer Information (Micromedex)
  • Pioglitazone Hydrochloride AHFS DI Monographs (ASHP)

Saturday 19 November 2011

Rumasin




Rumasin may be available in the countries listed below.


Ingredient matches for Rumasin



Methyl Salicylate

Methyl Salicylate is reported as an ingredient of Rumasin in the following countries:


  • Turkey

International Drug Name Search

Friday 18 November 2011

Xuric




Xuric may be available in the countries listed below.


Ingredient matches for Xuric



Colchicine

Colchicine is reported as an ingredient of Xuric in the following countries:


  • Argentina

International Drug Name Search

Solubron




Solubron may be available in the countries listed below.


Ingredient matches for Solubron



Bromhexine

Bromhexine is reported as an ingredient of Solubron in the following countries:


  • Peru

International Drug Name Search

Thursday 17 November 2011

Pargine




Pargine may be available in the countries listed below.


Ingredient matches for Pargine



Arginine

Arginine aspartate (a derivative of Arginine) is reported as an ingredient of Pargine in the following countries:


  • Luxembourg

International Drug Name Search

Metronidazol DAK




Metronidazol DAK may be available in the countries listed below.


Ingredient matches for Metronidazol DAK



Metronidazole

Metronidazole is reported as an ingredient of Metronidazol DAK in the following countries:


  • Denmark

International Drug Name Search

Wednesday 16 November 2011

Gemfibrozilo Medifarma




Gemfibrozilo Medifarma may be available in the countries listed below.


Ingredient matches for Gemfibrozilo Medifarma



Gemfibrozil

Gemfibrozil is reported as an ingredient of Gemfibrozilo Medifarma in the following countries:


  • Peru

International Drug Name Search

Tuesday 15 November 2011

Riachol




Riachol may be available in the countries listed below.


Ingredient matches for Riachol



Chloramphenicol

Chloramphenicol is reported as an ingredient of Riachol in the following countries:


  • Oman

International Drug Name Search

Friday 11 November 2011

Ibuprofeno Pensa




Ibuprofeno Pensa may be available in the countries listed below.


Ingredient matches for Ibuprofeno Pensa



Ibuprofen

Ibuprofen is reported as an ingredient of Ibuprofeno Pensa in the following countries:


  • Spain

International Drug Name Search

Tuesday 8 November 2011

Glipizide-Merck




Glipizide-Merck may be available in the countries listed below.


Ingredient matches for Glipizide-Merck



Glipizide

Glipizide is reported as an ingredient of Glipizide-Merck in the following countries:


  • Luxembourg

International Drug Name Search

Lexmox-DC




Lexmox-DC may be available in the countries listed below.


Ingredient matches for Lexmox-DC



Amoxicillin

Amoxicillin is reported as an ingredient of Lexmox-DC in the following countries:


  • India

Dicloxacillin

Dicloxacillin is reported as an ingredient of Lexmox-DC in the following countries:


  • India

International Drug Name Search

Monday 7 November 2011

Gadral




Gadral may be available in the countries listed below.


Ingredient matches for Gadral



Magaldrate

Magaldrate is reported as an ingredient of Gadral in the following countries:


  • Italy

International Drug Name Search

Thursday 3 November 2011

Gen-Lisinopril




Gen-Lisinopril may be available in the countries listed below.


Ingredient matches for Gen-Lisinopril



Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Gen-Lisinopril in the following countries:


  • Canada

International Drug Name Search

Wednesday 2 November 2011

Rilutek


Generic Name: riluzole (RIL yoo zol)

Brand Names: Rilutek


What is Rilutek (riluzole)?

Riluzole works by decreasing your body's levels of glutamate, an amino acid that affects nerves that send messages from your brain to your muscles. People with amyotrophic lateral sclerosis may have very high levels of glutamate, which can damage these nerve cells.


Riluzole is used to treat amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease.


Riluzole is not a cure for ALS, but it may delay progression of the disease and prolong your life.

Riluzole may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Rilutek (riluzole)?


You should not use this medication if you are allergic to riluzole.

Before you take riluzole, tell your doctor if you have liver or kidney disease.


Riluzole may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Take riluzole on an empty stomach.

To be sure this medication is not causing harmful effects, your blood will need to be tested often. Visit your doctor regularly.


Avoid drinking alcohol. It may increase your risk of liver damage. Avoid products that contain caffeine. Caffeine may cause too much riluzole to build up in your body. Smoking cigarettes may make riluzole less effective.

What should I discuss with my healthcare provider before taking Rilutek (riluzole)?


You should not use this medication if you are allergic to it.

If you have liver or kidney disease, you may need a dose adjustment or special tests to safely use this medication:


FDA pregnancy category C. It is not known whether riluzole will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication. It is not known whether riluzole passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take Rilutek (riluzole)?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Take this medicine with a full glass of water. Take riluzole on an empty stomach, at least 1 hour before or 2 hours after a meal.

Riluzole is usually taken twice a day, every 12 hours. Follow your doctor's instructions. It is important to take your medicine at the same times each day.


To be sure this medication is not causing harmful effects, your liver function will need to be checked with blood tests every month during the first 3 months of treatment, and less often as treatment continues. Visit your doctor regularly.


Store at room temperature away from moisture, heat, and bright light.

See also: Rilutek dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Rilutek (riluzole)?


Riluzole may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid drinking alcohol. It may increase your risk of liver damage. Avoid coffee, tea, cola, or other products that contain caffeine. Caffeine may cause too much riluzole to build up in your body. Avoid smoking. Smoking cigarettes may make riluzole less effective.

Rilutek (riluzole) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Stop using riluzole and call your doctor at once if you have a serious side effect such as:

  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);




  • fever, chills, body aches, flu symptoms;




  • chest discomfort, dry cough, trouble breathing;




  • cough with yellow or green mucus; or




  • stabbing chest pain, feeling short of breath.



Less serious side effects may include:



  • dizziness, spinning sensation;




  • muscle stiffness;




  • weakness, drowsiness;




  • numbness or tingly feeling in or around your mouth;




  • mild nausea, diarrhea, stomach pain, constipation;




  • headache; or




  • runny nose.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Rilutek (riluzole)?


Many drugs can interact with riluzole. Below is just a partial list. Tell your doctor if you are using:



  • acetaminophen (Tylenol);




  • allopurinol (Zyloprim);




  • amitriptyline (Elavil, Vanatrip);




  • auranofin (Ridaura);




  • cancer medications




  • methyldopa (Aldomet);




  • omeprazole (Prilosec);




  • sulfasalazine (Azulfidine);




  • theophylline (Elixophyllin, Theo-24, Theochron, Uniphyl, and others);




  • tuberculosis medications;




  • birth control pills or other hormones;




  • methotrexate (Rheumatrex, Trexall);




  • an ACE inhibitor such as benazepril (Lotensin), enalapril (Vasotec), lisinopril (Prinivil, Zestril), quinapril (Accupril), ramipril (Altace), and others;




  • an antibiotic such as ciprofloxacin (Cipro), dapsone, erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), levofloxacin (Levaquin), norfloxacin (Noroxin), ofloxacin (Floxin), or rifampin (Rifater, Rifadin, Rifamate);




  • antifungal medication such as fluconazole (Diflucan), itraconazole (Sporanox), or ketoconazole (Extina, Ketozole, Nizoral, Xolegal);




  • cholesterol medications such as niacin (Advicor, Niaspan, Niacor, Slo-Niacin, and others), atorvastatin (Lipitor), simvastatin (Zocor, Simcor, Vytorin), lovastatin (Mevacor), pravastatin (Pravachol), and others;




  • HIV/AIDS medications such as abacavir/lamivudine/zidovudine (Trizivir), lamivudine (Combivir, Epivir), nevirapine (Viramune), tenofovir (Viread), or zidovudine (Retrovir);




  • an NSAID (non-steroidal anti-inflammatory drug) such as ibuprofen (Motrin, Advil), naproxen (Aleve, Naprosyn), diclofenac (Cataflam, Voltaren), etodolac (Lodine), indomethacin (Indocin), ketoprofen (Orudis), and others; or




  • seizure medications such as carbamazepine (Carbatrol, Tegretol), phenytoin (Dilantin), felbamate (Felbatol), valproic acid (Depakene).




This list is not complete and there are many other drugs that can interact with riluzole. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor. Keep a list of all your medicines and show it to any healthcare provider who treats you.

More Rilutek resources


  • Rilutek Side Effects (in more detail)
  • Rilutek Dosage
  • Rilutek Use in Pregnancy & Breastfeeding
  • Drug Images
  • Rilutek Drug Interactions
  • Rilutek Support Group
  • 0 Reviews for Rilutek - Add your own review/rating


  • Rilutek Prescribing Information (FDA)

  • Rilutek MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rilutek Monograph (AHFS DI)

  • Rilutek Advanced Consumer (Micromedex) - Includes Dosage Information

  • Riluzole Professional Patient Advice (Wolters Kluwer)



Compare Rilutek with other medications


  • Amyotrophic Lateral Sclerosis


Where can I get more information?


  • Your pharmacist can provide more information about riluzole.

See also: Rilutek side effects (in more detail)


Tuesday 1 November 2011

Mukolina




Mukolina may be available in the countries listed below.


Ingredient matches for Mukolina



Carbocisteine

Carbocisteine is reported as an ingredient of Mukolina in the following countries:


  • Poland

International Drug Name Search

Gadoversetamide




In the US, Gadoversetamide is a member of the drug class magnetic resonance imaging contrast media and is used to treat Magnetic Resonance Angiography.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

V08CA06

CAS registry number (Chemical Abstracts Service)

0131069-91-5

Chemical Formula

C20-H34-Gd-N5-O10

Molecular Weight

661

Therapeutic Category

Diagnostic agent

Chemical Names

[N,N-Bis[2-[[(carboxymethyl)[(2-methoxyethyl)carbamoyl]methyl]amino]ethyl]glycinato(3-)]gadolinium (WHO)

Gadolinium, [8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)]- (USAN)

Foreign Names

  • Gadoversetamidum (Latin)
  • Gadoversetamid (German)
  • Gadoversetamide (French)
  • Gadoversetamida (Spanish)

Generic Names

  • Gadoversetamide (OS: BAN, USAN)
  • MP 1177 (IS: MallinckrodtMe)
  • Gadoversetamide (PH: USP 32)

Brand Names

  • OptiMARK
    Covidien, Austria; Covidien, Belgium; Covidien, Luxembourg; Covidien Deutschland, Greece; Mallinckrodt, Argentina; Mallinckrodt, United States; Tyco, Canada; Tyco, Denmark; Tyco, Norway; Tyco Healthcare, Slovenia


  • Optimark
    Covidien, Sweden


  • Optimark (Gadoversetamide and Gadoversetamide)
    Mallinckrodt, Switzerland


  • Optimark (Gadoversetamide and Versetamide)
    Mallinckrodt, Switzerland

International Drug Name Search

Glossary

BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.